End-of-day quote
Shenzhen S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
61.12
CNY
|
+0.39%
|
|
+1.92%
|
+22.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
31,012
|
24,414
|
33,518
|
46,264
|
49,142
|
60,398
|
-
|
-
|
Enterprise Value (EV)
1 |
27,996
|
20,622
|
30,571
|
43,400
|
45,238
|
56,546
|
53,821
|
49,486
|
P/E ratio
|
14.7
x
|
15.3
x
|
16.4
x
|
18.9
x
|
17.1
x
|
18.1
x
|
15.8
x
|
14.1
x
|
Yield
|
1.36%
|
2%
|
2.51%
|
2.14%
|
3.02%
|
3.01%
|
3.09%
|
4.05%
|
Capitalization / Revenue
|
2.11
x
|
1.79
x
|
2.19
x
|
2.56
x
|
1.99
x
|
2.19
x
|
1.93
x
|
1.8
x
|
EV / Revenue
|
1.9
x
|
1.51
x
|
2
x
|
2.4
x
|
1.83
x
|
2.05
x
|
1.72
x
|
1.48
x
|
EV / EBITDA
|
9.67
x
|
8.26
x
|
10.4
x
|
12.5
x
|
10
x
|
11.3
x
|
9.5
x
|
7.93
x
|
EV / FCF
|
19.5
x
|
12.8
x
|
30.4
x
|
21.1
x
|
13.5
x
|
13.7
x
|
13.2
x
|
10.9
x
|
FCF Yield
|
5.13%
|
7.8%
|
3.29%
|
4.74%
|
7.43%
|
7.29%
|
7.55%
|
9.18%
|
Price to Book
|
2.47
x
|
1.78
x
|
2.19
x
|
2.72
x
|
2.59
x
|
2.86
x
|
2.53
x
|
2.22
x
|
Nbr of stocks (in thousands)
|
9,78,900
|
9,78,900
|
9,78,900
|
9,88,346
|
9,88,184
|
9,88,184
|
-
|
-
|
Reference price
2 |
31.68
|
24.94
|
34.24
|
46.81
|
49.73
|
61.12
|
61.12
|
61.12
|
Announcement Date
|
19/03/20
|
18/03/21
|
11/03/22
|
12/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
14,702
|
13,637
|
15,320
|
18,079
|
24,739
|
27,560
|
31,235
|
33,541
|
EBITDA
1 |
2,895
|
2,496
|
2,927
|
3,462
|
4,504
|
5,015
|
5,663
|
6,242
|
EBIT
1 |
2,529
|
2,070
|
2,457
|
2,947
|
3,753
|
4,338
|
5,015
|
5,651
|
Operating Margin
|
17.2%
|
15.18%
|
16.04%
|
16.3%
|
15.17%
|
15.74%
|
16.05%
|
16.85%
|
Earnings before Tax (EBT)
1 |
2,569
|
2,059
|
2,429
|
2,963
|
3,754
|
4,361
|
5,015
|
5,653
|
Net income
1 |
2,112
|
1,597
|
2,047
|
2,449
|
2,853
|
3,298
|
3,792
|
4,284
|
Net margin
|
14.37%
|
11.71%
|
13.36%
|
13.54%
|
11.53%
|
11.97%
|
12.14%
|
12.77%
|
EPS
2 |
2.160
|
1.630
|
2.090
|
2.480
|
2.900
|
3.385
|
3.865
|
4.347
|
Free Cash Flow
1 |
1,437
|
1,609
|
1,004
|
2,057
|
3,361
|
4,120
|
4,064
|
4,544
|
FCF margin
|
9.78%
|
11.8%
|
6.56%
|
11.38%
|
13.59%
|
14.95%
|
13.01%
|
13.55%
|
FCF Conversion (EBITDA)
|
49.64%
|
64.47%
|
34.31%
|
59.41%
|
74.62%
|
82.16%
|
71.76%
|
72.79%
|
FCF Conversion (Net income)
|
68.03%
|
100.73%
|
49.06%
|
83.98%
|
117.81%
|
124.92%
|
107.17%
|
106.08%
|
Dividend per Share
2 |
0.4300
|
0.5000
|
0.8600
|
1.000
|
1.500
|
1.838
|
1.888
|
2.476
|
Announcement Date
|
19/03/20
|
18/03/21
|
11/03/22
|
12/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
|
4,221
|
4,194
|
4,207
|
3,710
|
5,969
|
6,352
|
6,794
|
5,462
|
6,131
|
7,294
|
-
|
-
|
-
|
6,719
|
8,063
|
EBITDA
1 |
558.1
|
1,087
|
802.2
|
853.8
|
-
|
-
|
-
|
-
|
-
|
-
|
1,178
|
1,260
|
1,424
|
1,150
|
1,336
|
EBIT
|
315.8
|
1,023
|
792.6
|
607
|
525.2
|
1,514
|
985.1
|
751.3
|
503.1
|
1,798
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
7.48%
|
24.38%
|
18.84%
|
16.36%
|
8.8%
|
23.83%
|
14.5%
|
13.75%
|
8.21%
|
24.65%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
316.1
|
1,021
|
794.3
|
612.4
|
535.8
|
1,510
|
985.6
|
754.3
|
504.7
|
1,803
|
1,040
|
1,127
|
1,300
|
983.2
|
1,180
|
Net income
|
305.7
|
838.7
|
594.4
|
519.3
|
496.5
|
1,151
|
726.1
|
525.5
|
450.3
|
1,364
|
-
|
-
|
-
|
697.8
|
837.3
|
Net margin
|
7.24%
|
20%
|
14.13%
|
14%
|
8.32%
|
18.12%
|
10.69%
|
9.62%
|
7.35%
|
18.7%
|
-
|
-
|
-
|
10.39%
|
10.39%
|
EPS
2 |
0.3100
|
0.8600
|
0.6000
|
0.5300
|
0.4900
|
1.160
|
0.7500
|
0.5300
|
0.4600
|
1.390
|
0.9000
|
0.5400
|
0.6400
|
1.123
|
1.094
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.262
|
-
|
-
|
-
|
1.412
|
Announcement Date
|
11/03/22
|
22/04/22
|
23/08/22
|
28/10/22
|
12/03/23
|
28/04/23
|
29/08/23
|
27/10/23
|
22/03/24
|
19/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3,016
|
3,791
|
2,946
|
2,864
|
3,904
|
3,852
|
6,577
|
10,911
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,437
|
1,609
|
1,004
|
2,057
|
3,361
|
4,120
|
4,064
|
4,544
|
ROE (net income / shareholders' equity)
|
18.1%
|
12.1%
|
14.1%
|
15.2%
|
15.9%
|
15.6%
|
16.3%
|
16.3%
|
ROA (Net income/ Total Assets)
|
11.1%
|
7.36%
|
8.84%
|
9.48%
|
-
|
8.95%
|
8.67%
|
9.21%
|
Assets
1 |
19,068
|
21,705
|
23,159
|
25,832
|
-
|
36,845
|
43,760
|
46,517
|
Book Value Per Share
2 |
12.80
|
14.00
|
15.60
|
17.20
|
19.20
|
21.30
|
24.10
|
27.50
|
Cash Flow per Share
2 |
2.010
|
2.270
|
1.910
|
3.040
|
4.240
|
5.350
|
4.740
|
6.090
|
Capex
1 |
535
|
615
|
866
|
950
|
831
|
1,881
|
1,133
|
1,359
|
Capex / Sales
|
3.64%
|
4.51%
|
5.65%
|
5.25%
|
3.36%
|
6.82%
|
3.63%
|
4.05%
|
Announcement Date
|
19/03/20
|
18/03/21
|
11/03/22
|
12/03/23
|
22/03/24
|
-
|
-
|
-
|
Last Close Price
61.12
CNY Average target price
69.33
CNY Spread / Average Target +13.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.90% | 8.36B | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|